Presented by Robert Reiter, MD, MBA
About the Lecture
Prostate cancer continues to be the leading cancer diagnosis in men, with over 200,000 cases detected yearly. Although PSA screening has been shown to reduce the death rate from prostate cancer, it remains highly controversial and has led to recommendations to stop screening protocols in the US. The controversy stems from the fact that prostate cancers have a wide spectrum of malignancy. Some cancers grow slowly and pose little or no threat, while others spread rapidly and are lethal. The management of prostate cancer has changed dramatically in the past five years. The nature of the controversy regarding prostate screening and current and promising approaches to retain the benefits of screening while avoiding its harms will be described. In particular, novel imaging techniques and molecular tests that can help physicians and patients make better decisions will be reviewed. Finally, for those with aggressive forms of prostate cancer, some of the newest research and advances in both diagnostic testing and drug development will be discussed. In particular, some of the discoveries made at UCLA that have revolutionized the diagnosis and management of this disease will be highlighted.
About the Speaker
Robert Reiter, MD, MBA Bing Professor of Prostate Cancer in the Department of Urology and the Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA, Director of the Prostate Cancer Treatment and Research Program, Principal investigator of UCLA’s Prostate Cancer SPORE, a 12 million dollar NCI funded program to research and translate to the clinic new treatments and diagnostic tests for prostate cancer. His laboratory research is focused on discovering new therapies and imaging tests for prostate cancer. In addition, Dr. Reiter has an active clinical practice focused on men with prostate cancer. In particular, he specializes in robotic prostatectohly and is leader of UCLA’s robotic surgery program. He also started an innovative program in collaboration with the Department of Radiology to use MRI to manage prostate cancer, which has evolved into one of the busiest and most advanced imaging programs in the nation.